Abigerges D, Armand J P, Chabot G G, Da Costa L, Fadel E, Cote C, Hérait P, Gandia D
Institut Gustave-Roussy, Villejuif, France.
J Natl Cancer Inst. 1994 Mar 16;86(6):446-9. doi: 10.1093/jnci/86.6.446.
Diarrhea is a serious side effect that may prevent the administration of high doses of the antitumor drug Irinotecan (CPT-11).
Intensive, high-dose loperamide was used in an attempt to control or downstage CPT-11-induced diarrhea and thus permit the use of higher dose intensities of CPT-11.
Twenty-three patients with various cancers were treated with doses of CPT-11 ranging from 400 to 600 mg/m2, administered as a 30-minute intravenous infusion every 3 weeks. Starting 8 hours or more after the administration of CPT-11, any episode of diarrhea was treated with 2 mg of loperamide taken every 2 hours. Patients stopped taking loperamide only after a 12-hour diarrhea-free period. If diarrhea was not controlled after 3 consecutive days of nonstop loperamide intake, or if the patient was dehydrated, loperamide was stopped and the patient was hospitalized for intravenous fluids. If blood or mucus were found in the stools at any time during diarrhea, loperamide was stopped and the patient was hospitalized.
Seventeen of 23 patients had diarrhea while on CPT-11 treatment. Eighty-two CPT-11 cycles were administered to these 17 patients, and diarrhea occurred in 49 of these cycles, at a median time-to-onset of 6 days after CPT-11 administration. The loperamide protocol was followed in 46 of the 49 episodes of diarrhea, with 21 capsules of loperamide the median number being taken (range, 5-72). Only one patient was hospitalized for failure to respond to loperamide, and no major toxicity was associated with loperamide use. Fourteen of the 17 patients who experienced diarrhea were rechallenged with CPT-11 three or more times, and seven patients six or more times.
High-dose loperamide controlled diarrhea in patients receiving CPT-11 and allowed administration of higher doses of CPT-11.
The effectiveness of CPT-11 might be increased by higher dose intensities, which can be made tolerable by control of diarrhea with loperamide.
腹泻是一种严重的副作用,可能会妨碍给予高剂量的抗肿瘤药物伊立替康(CPT-11)。
使用大剂量洛哌丁胺试图控制或减轻CPT-11引起的腹泻,从而允许使用更高剂量强度的CPT-11。
23例患有各种癌症的患者接受剂量为400至600mg/m²的CPT-11治疗,每3周静脉输注30分钟。在给予CPT-11后8小时或更长时间开始,任何腹泻发作均每2小时服用2mg洛哌丁胺进行治疗。患者仅在连续12小时无腹泻后才停止服用洛哌丁胺。如果连续3天不间断服用洛哌丁胺后腹泻仍未得到控制,或者患者出现脱水,则停止服用洛哌丁胺并将患者住院接受静脉补液。如果在腹泻期间的任何时候粪便中发现血液或黏液,则停止服用洛哌丁胺并将患者住院。
23例患者中有17例在接受CPT-11治疗期间出现腹泻。对这17例患者进行了82个CPT-11周期的治疗,其中49个周期出现腹泻,CPT-11给药后腹泻发作的中位时间为6天。49次腹泻发作中有46次遵循了洛哌丁胺方案,服用洛哌丁胺的中位数为21粒胶囊(范围为5-72粒)。只有1例患者因对洛哌丁胺无反应而住院,且使用洛哌丁胺未出现重大毒性。17例出现腹泻的患者中有14例接受了3次或更多次的CPT-11再激发治疗,7例患者接受了6次或更多次的再激发治疗。
高剂量洛哌丁胺可控制接受CPT-11治疗患者的腹泻,并允许给予更高剂量的CPT-11。
更高的剂量强度可能会提高CPT-11的有效性,通过用洛哌丁胺控制腹泻可使其变得可耐受。